A. Douglas Kinghorn PhD, DSc

A. Douglas Kinghorn PhD, DSc
ProfessorCollege of Pharmacykinghorn.4@osu.edu
446 Parks Hall 500 W 12th Avenue Columbus Ohio 43210
Phone:614-247-8094Fax: 614-247-8117
  • Molecular Carcinogenesis and Chemoprevention
  • Administrative

General Research Interest

Natural products; pharmacognosy; drug discovery; anticancer agents; cancer chemopreventive agents; natural sweetening agents; antimicrobial agents; tropical plants; edible plants

Research Description

Dr. Kinghorn has worked for about 30 years on the discovery of new anticancer agents from mainly tropical plants. For over a decade while at the University of Illinois at Chicago, Dr. Kinghorn served as Principal Investigator of a National Cooperative Drug Discovery Groups (NCDDG) project entitled "Novel Strategies for Plant-Derived Anticancer Agents" (U01/U19 CA52956; funded by the U.S. National Cancer Institute, Bethesda, MD, from which several good compound leads emerged, such as betulinic acid, pervilleine A, and silvestrol.  Dr. Kinghorn is currently Principal Investigator of a collaborative multidisciplinary program project entitled “Discovery of Anticancer Agents of Diverse Natural Origin” (P01 CA125066), again funded by NCI (2007-2012). The primary objective of this project is to discover new natural product anticancer agents from tropical plants, aquatic cyanobacteria, and filamentous fungi. Other research interests of Dr. Kinghorn's are on the investigation of botanical dietary supplements and edible plants for their potential cancer chemopreventive principles, the search for new sweeteners and taste-modifying agents from plants, and the investigation of plant principles for the treatment of tropical infectious diseases.

Transinstitutional Work

Program project  P01 CA125066 mentioned above is a formal collaboration between The Ohio State University, the University of Illinois at Chicago, the University of North Carolina-Greensboro, Bristol-Myers Squibb (Princeton, NJ), and Mycosynthetix (Hillsborough, NC). Other OSU faculty members involved with this program project are Dr. Esperanza Carcache de Blanco (College of Pharmacy) and Dr. David Jarjoura (Center for Biostatistics). Recently, Dr. Kinghorn has collaborated and co-published with Drs. Michael Grever and David Lucas (Division of Hematology and Oncology,  OSUMC), Drs. Steven D'Ambrosio and Haiming Ding (Department of Radiology, OSUMC), and Dr. Robert Brueggemeier (College of Pharmacy, OSU).

Current Publications

  • Jordan CTFlavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.Leukemia 2/28/2014
  • Bueno Pérez L, Pan L, Sass E, Gupta SV, Lehman A, Kinghorn A, Lucas DMPotentiating effect of the flavonolignan (-)-hydnocarpin in combination with vincristine in a sensitive and P-gp-expressing acute lymphoblastic leukemia cell line.Phytother Res 27 1735-8 11/1/2013
  • Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel TTherapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.PLoS One 8(9) e76136 9/26/2013
  • Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci GSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.J Hematol Oncol 6 21 3/16/2013
  • Chitchumroonchokchai C, Thomas-Ahner JM, Li J, Riedl KM, Nontakham J, Suksumrarn S, Clinton SK, Kinghorn AD, Failla MLAnti-tumorigenicity of dietary α-mangostin in an HT-29 colon cell xenograft model and the tissue distribution of xanthones and their phase II metabolites.Mol Nutr Food Res 57(2) 203-11 2/1/2013
  • Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn D, Baiocchi R, Grever MR, Lucas DMDual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Clin Cancer Res 18(17) 4600-11 9/1/2012
  • El-Elimat T, Zhang X, Jarjoura D, Moy FJ, Orjala J, Kinghorn AD, Pearce CJ, Oberlies NHChemical Diversity of Metabolites from Fungi, Cyanobacteria, and Plants Relative to FDA-Approved Anticancer Agents.ACS Med Chem Lett 3(8) 645-649 7/12/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu